Payment overview · 2025
General Payments
$347.49
12 reported records · 7 companies
Healthcare provider profile · identity verified
Terry Ray Perrine, MD
Allopathic & Osteopathic Physicians|Family Medicine · TUPELO, MS · NPI 1033157391
Verified facts
What the public records show
CMS Open Payments records show Terry Ray Perrine, MD received $347.49 in general payments during 2025 across 12 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 54.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lumigan by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Farxiga by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 378 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $190.65 | 54.9% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $55.19 | 15.9% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $34.49 | 9.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.54 | 5.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.49 | 5.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.58 | 4.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.55 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $347.49 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $190.65 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $55.19 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $55.19 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $55.19 | 3 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $34.49 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.54 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $13.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
378 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 823 | 45 |
| Levothyroxine Sodium | Levothyroxine Sodium | 485 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 481 | 27 |
| Eliquis | Apixaban | 378 | 20 |
| Omeprazole | Omeprazole | 361 | 24 |
| Donepezil Hcl | Donepezil Hcl | 352 | 18 |
| Gabapentin | Gabapentin | 327 | 35 |
| Amlodipine Besylate | Amlodipine Besylate | 290 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 256 | 13 |
| Lisinopril | Lisinopril | 252 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 247 | 12 |
| Famotidine | Famotidine | 246 | 15 |
| Carvedilol | Carvedilol | 238 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 232 | 12 |
| Sertraline Hcl | Sertraline Hcl | 227 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 201 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 169 | suppressed |
| Potassium Chloride | Potassium Chloride | 164 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 163 | 46 |
| Citalopram Hbr | Citalopram Hydrobromide | 162 | suppressed |
| Simvastatin | Simvastatin | 153 | suppressed |
| Losartan Potassium | Losartan Potassium | 149 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 145 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 141 | suppressed |
| Mirtazapine | Mirtazapine | 141 | suppressed |
| Furosemide | Furosemide | 136 | 20 |
| Digoxin | Digoxin | 123 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 123 | suppressed |
| Lorazepam | Lorazepam | 99 | 27 |
| Levetiracetam | Levetiracetam | 97 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 96 | suppressed |
| Memantine Hcl | Memantine Hcl | 82 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 81 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 79 | suppressed |
| Bupropion Xl | Bupropion Hcl | 78 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 77 | 11 |
| Meloxicam | Meloxicam | 77 | suppressed |
| Sucralfate | Sucralfate | 77 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 73 | suppressed |
| Spironolactone | Spironolactone | 73 | suppressed |
| Metformin Hcl | Metformin Hcl | 69 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 67 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 65 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 64 | suppressed |
| Ezetimibe | Ezetimibe | 61 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 61 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 59 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 59 | suppressed |
| Xarelto | Rivaroxaban | 58 | suppressed |
| Allopurinol | Allopurinol | 57 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 55 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 54 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 52 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 52 | suppressed |
| Methotrexate | Methotrexate Sodium | 52 | suppressed |
| Metolazone | Metolazone | 52 | suppressed |
| Primidone | Primidone | 52 | suppressed |
| Sotalol | Sotalol Hcl | 52 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 51 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 49 | suppressed |
| Clonazepam | Clonazepam | 48 | suppressed |
| Lovastatin | Lovastatin | 48 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 47 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 47 | 11 |
| Benazepril Hcl | Benazepril Hcl | 45 | suppressed |
| Pregabalin | Pregabalin | 44 | suppressed |
| Atenolol | Atenolol | 43 | suppressed |
| Jardiance | Empagliflozin | 43 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | suppressed |
| Phenobarbital | Phenobarbital | 38 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 38 | suppressed |
| Naproxen | Naproxen | 37 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 36 | suppressed |
| Alprazolam | Alprazolam | 34 | suppressed |
| Diazepam | Diazepam | 34 | suppressed |
| Prednisone | Prednisone | 34 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 32 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 32 | 12 |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Baclofen | Baclofen | 30 | suppressed |
| Cilostazol | Cilostazol | 30 | suppressed |
| Phenytoin | Phenytoin | 27 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 25 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 24 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 20 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 15 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Novolog | Insulin Aspart | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Cortef | Hydrocortisone | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Lumigan | Bimatoprost | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $347.49 · 12 records | Otsuka America Pharmaceutical, Inc. | ABRYSVO, AIRSUPRA, COMIRNATY, Dexcom G6 Transmitter, Kerendia, PREVNAR 20, REXULTI, VRAYLAR, WATCHMAN FLX | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error